Summarized by Masters of Longevity from FDA - Press Releases.
A news article about the approval of a novel targeted therapy for a rare neurological disorder, explaining what the report covers and why it matters to patients and clinicians.
Key Takeaways
- The FDA granted approval to zilganersen, marketed as Zanvastro, for treating Alexander disease in children and adults.
- This approval establishes the first approved pharmacologic therapy specifically indicated for Alexander disease.
- Zilganersen will be administered by injection as the approved route of delivery.
